XUE Nina
Xue's research interest is molecular pharmacology of anti-tumor agents and the development of new drugs. Targets involved are HSP90, STAT3, LAG3, PD1, etc . The main research topics at present are: 1. the mechanism of endogenous LAG3 in tumor microenvironment, establishment of the LAG3 screening platform and the searching for lead compounds; 2. the molecular mechanism of natural product on tumor immunotherapy.
1. A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models. Acta Pharmaceutica Sinica B .2020;10(2):276-288.
2. Chaperone-mediated autophagy degradation of IGF-1Rβ induced by NVP-AUY922 in pancreatic cancer. Cell Mol Life Sci. 2019; 76(17): 3433-3447.
3. Exploration of the Fluorescent Properties and the Modulated Activities against Sirtuin Fluorogenic Assays of Chromenone-Derived Natural Products. Molecules. 2018; 23(5) pii: E1063.
4. The Characteristics of Hepatic Gsalpha-cAMP Axis in HSHF Diet-Fed Obese Insulin Resistance Rats and Genetic Diabetic Mice. Biol Pharm Bull. 2017; 40(6): 774-781.
5. Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype. Sci Rep. 2017; 7: 39011.
6. Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways. Curr Cancer Drug Targets . 2014; 14(7): 671-683.
7. The optimization and application of cell-based screening model for IL-17-mediated signaling pathway. Acta Pharmaceutica Sinica. 2019,54(10):1858-1862.
8. Effect of different stimulants on the LAG3 expression and function of spleen lymphocytes in mice. Chinese Journal of Biochemical and Pharmaceutics. 2017, 28(2):1-4.
9. Development of the high-throughput screening fluorescence polarization assay for HSP90 inhibitor. Chinese Journal of Biochemical and Pharmaceutics. 2017, 28(2): 8-11.
10. CFSE-labeled proliferative assays for assessment of T cell function induced by different stimulants. Journal of Harbin University of Commerce (Natural Sciences Edition). 2017,33(2):129-134.
